why choose us

First received: July 19, 2022

Clinical Trial: Exploring the Molecular Mechanism Based on KIT Mutation

Study Status: Completed

Recruit Status: RECRUITING

Condition: GIST

Study Type: OBSERVATIONAL


Official Title: Exploring the Molecular Mechanism of Secondary Resistance to Imatinib in Gastrointestinal Stromal Tumors Based on KIT Mutation

Brief Summary: Imatinib remains suboptimal for recurrence/metastasis and unresectable GIST response rates.With the maturity of genomics and metabolomics, people gradually realize the role of gut microbiota in tumor therapy.The gut microbiota may affect tumor treatment by regulating the tumor microenvironment or the host immune system, and some bacteria can fight tumors by activating the immune system.Growing evidence shows that the effect of tumor therapy is related to the composition of the gut microbiota of patients, and…

Read more